<SEC-DOCUMENT>0001558370-18-008890.txt : 20181108
<SEC-HEADER>0001558370-18-008890.hdr.sgml : 20181108
<ACCEPTANCE-DATETIME>20181108060354
ACCESSION NUMBER:		0001558370-18-008890
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181107
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181108
DATE AS OF CHANGE:		20181108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amphastar Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001297184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330702205
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36509
		FILM NUMBER:		181167987

	BUSINESS ADDRESS:	
		STREET 1:		11570 SIXTH STREET
		CITY:			RANCHO CUCAMONGA
		STATE:			CA
		ZIP:			91730
		BUSINESS PHONE:		909-980-9484

	MAIL ADDRESS:	
		STREET 1:		11570 SIXTH STREET
		CITY:			RANCHO CUCAMONGA
		STATE:			CA
		ZIP:			91730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Merrill Bridge  8.2.0.61-->
<!--Created on: 11/8/2018 4:03:19 AM-->
<html>
	<head>
		<title>
			AMPH_Current_Folio_8K_NonFinancial
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 1.5pt;border-bottom:1pt solid #000000 ;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 15pt;">
			<font style="display:inline;font-weight:bold;font-size:15pt;">UNITED STATES </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 15pt;">
			<font style="display:inline;font-weight:bold;font-size:15pt;">SECURITIES AND EXCHANGE COMMISSION </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Washington, D.C. 20549 </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 1.5pt;border-bottom:1pt solid #000000 ;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 15pt;">
			<font style="display:inline;font-weight:bold;font-size:15pt;">FORM 8-K </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 1.5pt;border-bottom:1pt solid #000000 ;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">CURRENT REPORT </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Date of Report (Date of earliest event reported)&nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">November 7, 2018</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 1.5pt;border-bottom:1pt solid #000000 ;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 20pt;">
			<font style="display:inline;font-weight:bold;font-size:20pt;">Amphastar Pharmaceuticals, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">(Exact name of Registrant as specified in its charter) </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 1.5pt;border-bottom:1pt solid #000000 ;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="middle" style="width:33.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:31.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:31.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a name="StartOfCellsToJoin"></a><a name="CellsToJoin"></a><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:31.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:31.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:33.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Delaware</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:7pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">001-36509</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:7pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">33-0702205</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:33.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">(State or other jurisdiction of</font></p>
					<p style="margin:0pt 0pt 0.75pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">incorporation)</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:7pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">(Commission</font></p>
					<p style="margin:0pt 0pt 0.75pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">File Number)</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:7pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">(IRS Employer</font></p>
					<p style="margin:0pt 0pt 0.75pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">11570 6th Street<br />Rancho Cucamonga, California 91730</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
			<font style="display:inline;font-weight:bold;font-size:7pt;">(Address of principal executive offices, including zip code)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">(909) 980-9484</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
			<font style="display:inline;font-weight:bold;font-size:7pt;">(Registrant&#x2019;s telephone number, including area code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Not Applicable<br /></font><font style="display:inline;font-weight:bold;font-size:7pt;">(Former name or former address, if changed since last report)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 1.5pt;border-bottom:1pt solid #000000 ;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x25FB;</font></p>
				</td>
				<td valign="top" style="width:96.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:96.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x25FB;</font></p>
				</td>
				<td valign="top" style="width:96.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:96.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x25FB;</font></p>
				</td>
				<td valign="top" style="width:96.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:96.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x25FB;</font></p>
				</td>
				<td valign="top" style="width:96.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:126.67%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#xA7;240.12b-2 of this chapter).</font>
		</p>
		<p style="margin:0pt;line-height:126.67%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:126.67%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Emerging growth company &#x2611;</font>
		</p>
		<p style="margin:0pt;line-height:126.67%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:126.67%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2611;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 1.5pt;border-bottom:1pt solid #000000 ;border-top:1pt none #D9D9D9 ;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">ITEM 8.01.<font style="display:inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Other Events.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">On November 7, 2018, the Company issued a press release announcing the approval of its new drug application for Primatene</font><font style="display:inline;color:#000000;font-size:10pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;color:#000000;font-size:10pt;"> Mist (epinephrine inhalation aerosol bronchodilator suspension).</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">A copy of the press release is being filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">ITEM 9.01.<font style="display:inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Financial Statements and Exhibits.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(d) Exhibits</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;background-color: #FFFFFF;">
			<tr>
				<td valign="middle" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:88.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.08%;border-bottom:1pt solid #000000 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit&nbsp;No.</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:88.88%;border-bottom:1pt solid #000000 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.75pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:10.08%;border-top:1pt solid #000000 ;background-color: #FFFFFF;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:89.92%;background-color: #FFFFFF;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.08%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;99.1</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:88.88%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-99d1.htm"><font style="display:inline;font-size:10pt;">Press Release&nbsp;dated November 7, 2018 issued by Amphastar Pharmaceuticals, Inc.</font></a></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">SIGNATURES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<a name="page_2_1"></a><a name="doc_2"></a><font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:31.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="top" style="width:42.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">AMPHASTAR PHARMACEUTICALS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Date: November 8, 2018</font></p>
				</td>
				<td colspan="3" valign="top" style="width:42.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">By:</font></p>
				</td>
				<td valign="top" style="width:27.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">/S/WILLIAM J. PETERS</font></p>
				</td>
				<td valign="top" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="top" style="width:42.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">William J. Peters</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="top" style="width:42.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Chief Financial Officer and Senior Vice President</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="top" style="width:42.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Merrill Bridge  8.2.0.61-->
<!--Created on: 11/8/2018 4:03:18 AM-->
<html>
	<head>
		<title>
			amph_Ex99_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt 0pt 9pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene</font><font style="font-weight:bold;color:#008CA3;font-size:10.5pt;display:inline;color:#000000;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="font-weight:bold;color:#008CA3;font-size:10.5pt;display:inline;color:#000000;"> MIST</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:81.58%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:01.42%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:17.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.58%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">Primatene</font><font style="font-weight:bold;color:#008CA3;font-size:10.5pt;display:inline;color:#000000;font-size:12pt;font-size:6pt;top:-4.8pt;position:relative;line-height:100%">&#xAE;</font><font style="font-weight:bold;color:#008CA3;font-size:10.5pt;display:inline;color:#000000;font-size:12pt;">&nbsp;</font><font style="font-weight:bold;color:#008CA3;font-size:10.5pt;display:inline;font-weight:normal;color:#000000;font-size:12pt;">MIST</font><font style="font-weight:bold;color:#008CA3;font-size:10.5pt;display:inline;font-weight:normal;font-style:italic;color:#000000;font-size:12pt;"> fills unmet medical need as the only FDA approved over-the-counter asthma inhaler</font></p>
					<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 9pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-weight:bold;font-size:11pt;">RANCHO CUCAMONGA, CA </font><font style="display:inline;font-size:11pt;">&#x2013; November 7, 2018 &#x2013; Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (FDA) granted approval of its New Drug Application (NDA) for Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST (epinephrine inhalation aerosol bronchodilator suspension), which is delivered by a metered dose inhaler (MDI) with a non-chlorofluorocarbon (CFC) propellant. Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST is the only FDA-approved asthma inhaler available without a prescription in the United States. Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST is indicated for the temporary relief of mild symptoms of intermittent asthma in people ages 12 and above.&nbsp; </font></p>
					<p style="margin:9pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">Amphastar&#x2019;s CEO, Dr. Jack Zhang, stated: &#x201C;We are very happy to have received FDA approval for Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST and are proud to bring this important product back to the over-the-counter (OTC) market in the United States. We are grateful to the FDA team for working closely with us to make this approval possible, recognizing the important role of OTC bronchodilator drugs such as Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST. Amphastar&#x2019;s mission is to develop and bring to market innovative pharmaceutical products and delivery systems that will meaningfully improve peoples&#x2019; lives and we believe Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST will do just that.&#x201D; The newly approved, patented formulation of Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST is made with the same active ingredient, epinephrine, which was used in the original Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> Mist before it was removed from the market in 2011 for environmental reasons pursuant to the Montreal Protocol, an important international environmental treaty, which phased out products worldwide containing ozone-depleting CFCs. The product&#x2019;s new inhalation delivery system no longer includes CFC as the propellant and has other significant new features, including a built-in spray indicator and a metal canister, which replaces the glass container used in the original Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> Mist product.</font></p>
					<p style="margin:0pt 0pt 9pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">According to the Centers for Disease Control and Prevention National Center for Health Statistics, approximately 20 million adults in the United States suffer from asthma. Amphastar is pleased to bring back Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST as an OTC option for the temporary relief of mild symptoms of intermittent asthma. For more information, visit www.Primatene.com. &nbsp;</font></p>
					<p style="margin:0pt 0pt 9pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">Amphastar anticipates that Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> MIST will be available in major drug stores across the United States in early 2019.</font></p>
					<p style="margin:0pt 0pt 11.25pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-weight:bold;font-size:11pt;">Pipeline Information</font></p>
					<p style="margin:0pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">The Company currently has four abbreviated new drug applications (&#x201C;ANDAs&#x201D;) filed with the&nbsp;FDA, which are targeting products with a market size of approximately&nbsp;$0.7 billion, three biosimilar products in development targeting products with a market size of&nbsp;approximately $14.0 billion, and 11 generic products in development targeting products with a market size of approximately&nbsp;$12.0 billion. This market information is based on&nbsp;IQVIA&nbsp;data for the 12 months ended&nbsp;September 30, 2018. The Company&#x2019;s proprietary pipeline includes an NDA for intranasal naloxone. The Company is currently developing four other proprietary products, which include injectable, inhalation and intranasal dosage forms. </font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:01.42%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;color:#666666;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:17.00%;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;color:#666666;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-weight:bold;color:#666666;font-size:11pt;">Primatene Mist</font></p>
					<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#666666;font-family:Times New Roman,Times,serif;font-size: 3pt;">
						<font style="display:inline;font-size:3pt;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;"><img src="ex-99d1g001.jpg" style="width: 1.059738in; height: 3in" alt="Picture 1"></font></p>
					<p style="margin:6pt 0pt 0pt;line-height:100%;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;color:#666666;font-size:9pt;">Primatene Mist</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 11.25pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">Company Information</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">Amphastar is a specialty pharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation and intra-nasal products. Additionally, the Company sells insulin API products. Most of the Company&#x2019;s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company&#x2019;s website at&nbsp;www.amphastar.com.</font>
		</p>
		<p style="margin:0pt 0pt 11.25pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 11.25pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">Amphastar&#x2019;s logo and other trademarks or service marks of&nbsp;Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;">, Amphadase</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;">&nbsp;and Cortrosyn</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;">, are the property of&nbsp;Amphastar Pharmaceuticals, Inc.</font>
		</p>
		<p style="margin:0pt 0pt 11.25pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">Forward Looking Statements</font>
		</p>
		<p style="margin:0pt 0pt 11.25pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company&#x2019;s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including DMFs, the timing of product launches and the timing of products becoming available on the market,&nbsp;&nbsp;acquisitions and other matters related to its current products, pipeline of product candidates and other future events. These statements are not historical facts but rather are based on Amphastar&#x2019;s historical performance and its current expectations, estimates, and projections regarding Amphastar&#x2019;s business, operations, and other similar or related factors. Words such as &#x201C;may,&#x201D; &#x201C;might,&#x201D; &#x201C;will,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;should,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;predict,&#x201D; &#x201C;potential,&#x201D; &#x201C;continue,&#x201D; &#x201C;expects,&#x201D; &#x201C;intends,&#x201D; &#x201C;plans,&#x201D; &#x201C;projects,&#x201D; &#x201C;believes,&#x201D; &#x201C;estimates,&#x201D; and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar&#x2019;s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar&#x2019;s filings with the Securities and Exchange Commission. You can locate these reports through the Company&#x2019;s website at http://ir.amphastar.com and on the SEC&#x2019;s website at www.sec.gov.&nbsp;&nbsp;Amphastar undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar&#x2019;s expectations to change.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">Media Contact:<br /></font><font style="display:inline;font-size:11pt;">The Levinson Group<br />Kaye Verville</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">kaye@mollylevinson.com<br />(202) 244-1785</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 11.25pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">Investor Contact:<br /></font><font style="display:inline;font-size:11pt;">Amphastar Pharmaceuticals, Inc.<br />Bill Peters<br />Chief Financial Officer<br />(909) 980-9484</font>
		</p>
		<p style="margin:0pt 0pt 11.25pt;background-color: #FFFFFF;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">Noted products are trademarks or registered trademarks of their respective owners</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">Source: Amphastar Pharmaceuticals, Inc.</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! @$ = !T  #_[@ .061O8F4 9      !_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5JGJ6JV&D0?:-0F6%,X&>68^@ R36)XB\;66D;K6RVW=X." ?W2'_:(ZGV'
MZ5P5U/>ZLYU/5YV93PK'Y<_["#L/I42J):(TA2<M7L>A_P#">^&?^?EO^_4G
M_P 31_PGOAG_ )^6_P"_4G_Q->>"SCV!Q&$<C)1B2!]VG?9+=1EE^4, 6; !
MY]?N\U'M6:>QCW/0?^$]\,?\_+?]^I/_ (FC_A/?#'_/RW_?J3_XFN!^SQ9W
M/&J!2<Y7!^7=_L_2HUAC39')&H9N 2O5OO$$[<'M@4>U8>PCYGH7_">^&/\
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MI%83QI;RF0A=^]=HP<LH (;KQ50Y/)))/4FDQJXG%(>GX4N*".#0,Z3(]?\
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MUO?RVC*\8;*?=*X)'X&LVKG;@L1&ASJ7N\W_ *4;-I874=W&J.B3!9),,-P
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MD?GVK*I0C/K:7]W0:D6OL=HVU3!$VQ=@^13A1R!T]JD^S6Q8,T$9<*J@E%+
M#&!T]A5-&,9*(X4DD$ C=D#)'Y4]9)@AC5C@Y![L".M0L/*.TV)M=BPEK:1Y
M6*"-,J4(5%7*GJ#@=.:9):6KMOD@C+L  75-V!T[5$TDS($9B OX$_I3#NE/
MS-OV\=>A_"AX>3WFPNET%>#3HV(,,>]#N'[M2,GY@>%]:AF>2<+Y@7Y>F >:
MD\OGD?7/6CR_:M*=%0=]W_>U'<K[/:DV5:\KVH\KVK2PKDFWV_S^5%2^6/3_
M #^5%78FXIC^8_6CR_:K1BY/UI/)-'*+F*%U:_:+:6#C]Y&Z\Y&"1QGO6$-!
MDGE=8KF%]KJSIR2"N58\#MC@?RKK/*(ZBL.3PF)+B2<7+*)9A*5"8_B=B/O=
M?F'Y4G$<9%&ZTHM>S7D5[%#YV98P6(P&4@$$<8^6GQZ+J ?:MX/G5G8!Y,MN
MVC<>/UZU?NO# N8K6,3F/[+$8\A3AL$$9&[TS4$_A6<1,+>?S&9V(60$* Q&
M22=W( XI<K'SHBM=,NOM<,[72SQQS/,J%F8XSC(XZ@U!_95V)C%;W44:22S<
M1L5PY&[;CJ6QSSG Z&M:R\._8KL70D5_8H<@E@Y(.[K4W]AJLPGC959;M[A!
ML&!OC\LK^?)I\K%SHQSIU]-=,MM>;D$FUT25LQC:Q&[G@[@,8K7L[::"UBBG
M8/*B89P2<GZD U%<Z)<27L-TKJV+OSI<Y7"@)A1][/W3^=:OE>U"B#D5O+/I
M1Y?M5GR31Y5/E)YB+;[?Y_*BIO+/H?\ /X45=A7+7EC/KS1Y0]***JR(N'EC
MTH\L>E%%( \H>E'E#THHH"[#RQZ4>6/2BB@ \L4>6/2BB@ \L>E'EBBB@!FQ
*?7_/Y4444P/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
